Insider Selling: Haemonetics (NYSE:HAE) CAO Sells $101,147.64 in Stock

Haemonetics Corporation (NYSE:HAE) CAO Farris Maryanne Maunsell sold 836 shares of the firm’s stock in a transaction on Wednesday, November 11th. The shares were sold at an average price of $120.99, for a total transaction of $101,147.64. Following the transaction, the chief accounting officer directly owned 5,828 shares of the company’s stock, valued at $705,129.72. The trade was a 12.55% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Haemonetics Trading Up 0.4%

Shares of NYSE:HAE traded up $0.45 during mid-day trading on Friday, reaching $123.16. 439,677 shares of the company’s stock were exchanged, compared to its average volume of 808,065. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.83 and a current ratio of 2.84. Haemonetics Corporation has a twelve month low of $51.00 and a twelve month high of $132.00. The firm has a market capitalization of $5.61 billion, a price-to-earnings ratio of 55.23, a PEG ratio of 2.41 and a beta of 0.63. The business’s fifty day moving average price is $112.93 and its 200-day moving average price is $81.08.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $1.35 earnings per share for the quarter, beating analysts’ consensus estimates of $1.29 by $0.06. The business had revenue of $357.76 million during the quarter, compared to the consensus estimate of $345.15 million. Haemonetics had a return on equity of 27.42% and a net margin of 7.52%. Haemonetics’s quarterly revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the business posted $1.27 earnings per share. On average, research analysts predict that Haemonetics Corporation will post 5.32 EPS for the current fiscal year.

Analysts Set New Price Targets

HAE has been the topic of a number of analyst reports. Wall Street Zen lowered Haemonetics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 7th. Weiss Ratings reiterated a “hold (c)” rating on shares of Haemonetics in a report on Wednesday, November 4th. Mizuho set a $165.00 target price on Haemonetics in a report on Thursday, November 5th. Barrington Research boosted their price target on Haemonetics from $140.00 to $145.00 and gave the company an “outperform” rating in a research note on Friday, November 6th. Finally, Raymond James Financial increased their price target on Haemonetics from $105.00 to $125.00 and gave the stock an “outperform” rating in a report on Thursday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, Haemonetics presently has an average rating of “Moderate Buy” and a consensus price target of $129.00.

Institutional Investors Weigh In On Haemonetics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Bessemer Group Inc. raised its position in shares of Haemonetics by 53.7% during the third quarter. Bessemer Group Inc. now owns 269 shares of the medical instruments supplier’s stock worth $28,000 after purchasing an additional 94 shares during the period. Fortitude Family Office LLC grew its position in Haemonetics by 104.5% in the 3rd quarter. Fortitude Family Office LLC now owns 272 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 139 shares during the period. Root Financial Partners LLC acquired a new stake in Haemonetics in the 3rd quarter valued at $40,000. Kelleher Financial Advisors acquired a new stake in Haemonetics in the 2nd quarter valued at $38,000. Finally, Northwestern Mutual Wealth Management Co. bought a new stake in Haemonetics during the 2nd quarter valued at $44,000. Institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation is a global medical technology company focused on blood and plasma collection, processing and management. Its products and services are used by plasma collection organizations, blood centers and hospitals. The company provides automated plasma collection systems and related software and supplies, as well as technologies for collecting and processing blood components. Its hospital offerings include devices for surgical blood salvage and tools that help clinicians assess blood clotting and guide transfusion decisions.